The Many Faces of Interleukin-6: The Role of IL-6 in Inflammation, Vasculopathy, and Fibrosis in Systemic Sclerosis PDF Print E-mail
Wednesday, 21 March 2012 20:39
Theresa C. Barnes,Marina E. Anderson, and Robert J.Moots
Received 1 June 2011; Accepted 21 July 2011

Systemic sclerosis (SSc) is a connective tissue disease characterised by fibrosis, vasculopathy, and immunological abnormalities. Over recent years, it has become clear that inflammation plays a crucial role in mediating the pathophysiological process underlying SSc, especially early in the disease. Endothelial cell activation and dysfunction are central to the disease pathogenesis, may be driven by a proinflammatory environment, and may result in the generation of a profibrotic phenotype.

Interleukin-6 (IL-6) is a pleiotropic cytokine. In addition to its role in the acute phase response, IL-6 has diverse roles in driving chronic inflammation, autoimmunity, endothelial cell dysfunction, and fibrogenesis. Therefore, it is currently attracting a great deal of interest in the rheumatology community as a potential therapeutic agent in SSc, a disease which at present lacks treatments directed at the underlying pathogenesis.

Recent evidence has suggested that IL-6 may play important roles in endothelial cell dysfunction and fibrogenesis in this disease, and clinical trials are currently being designed to further explore whether Tocilizumab, a monoclonal antibody directed against the IL-6 receptor, may be of therapeutic benefit to patients with SSc.

Continue reading the full review article, by downloading it from the link provided below.

 
More articles :

» Lupus and Rheumatoid Arthritis Affect Birth Rates

suggests that more than half of women with the autoimmune diseases (RA) and (SLE, or Lupus) have fewer children than they had desired.According to a study published Thursday in the journal Arthritis Care & Research (a journal of the American...

» A Simple Blood Test Could Hold The Clue...

In a recent press release, the reported that a simple blood test could hold the clue and may even save lives. is a common condition, especially in teenagers, affecting approximately 10 million people in the UK. It can vary from being mild to very...

» The Impact Of Art On Wellbeing In Autoimmune Disease

An innovative Newcastle research project is measuring the impact of creating art on the symptoms and overall wellbeing of people living with an autoimmune illness.A team at the University of Newcastle, in conjunction with the at John Hunter...

» Clinical Significance of Antibodies to Ro52/TRIM21 in Systemic Sclerosis

Marie Hudson, Janet Pope, Michael Mahler, Solene Tatibouet, Russell Steele, Murray Baron, Canadian Scleroderma Research Group (csrg) and Marvin J FritzlerArthritis Research & Therapy 2012, 14:R50 doi:10.1186/ar3763Published: 6 March...

» Pain Common in Systemic Sclerosis

Pain is common and can be severe in patients with systemic sclerosis, a cross-sectional analysis found.Among patients enrolled in the multicenter Canadian Scleroderma Research Group Registry, 83% experienced pain, more than one-third of them...

» No Exercise Benefit with Bosentan in Systemic Sclerosis

Treatment with the endothelin receptor antagonist bosentan () failed to improve exercise capacity in patients with systemic sclerosis, a randomized trial found. After one year of treatment, there was a nonsignificant mean change in the six-minute...